Jetzt bei Plus500 CFDs auf die weltweit gefragtesten Basiswerte wie Aktien, Indizes oder Kryptowährungen entdecken!5 -W-
07.11.2019 20:38:00

Civis Analytics Kicks off "Voice of the Patient" Research Series with New Studies on Telehealth and HPV Vaccination

CHICAGO, Nov. 7, 2019 /PRNewswire/ -- Data science firm Civis Analytics today launched its Voice of the Patient research initiative, designed to increase understanding of consumer attitudes and motivators related to healthcare. The first studies in the series, also released today, sought to answer two distinct questions:

Civis Analytics helps leading public and private sector organizations use data to gain a competitive advantage in how they identify, attract, and engage people. With a blend of proprietary data, technology and advisory services, and an interdisciplinary team of data scientists, developers, and survey science experts, Civis helps organizations stop guessing and start using statistical proof to guide decisions. Learn more about Civis at www.civisanalytics.com.

  • What does the telehealth market look like today, and where is the greatest demand for the future? (Meeting Demand for Telehealth)
  • How do parents feel about HPV vaccinations, and how do you persuade them to follow HPV vaccination recommendations? (Improving Support for HPV Vaccination Through Persuasive Messaging)
  • An overview of each report follows.

    Meeting Demand for Telehealth 
    In June 2019, Civis surveyed 2,840 U.S. adults, weighted to be representative of the American public. Relevant findings include:

    There is significant interest in telehealth services, but few patients have actually used them: Only 9% have used telehealth services, and they are more likely to be young, male, and from a rural community. However, 68% of those who have not used telehealth services are interested in doing so in the future.

    • To date, virtual care is most frequently used for consultations related to mild conditions such as acid reflux and pink eye, followed by prescription refills.

    Patients are particularly interested in virtual care for mental health services, prescription refills and sexual health consultations: 57% of those that plan to use mental health services expressed interest in virtual consultations. There is also a high interest in telehealth for prescription refills (46%) and sexual health consultations (40%).

    • These three use-cases are also the biggest motivating factors for switching from a traditional provider. 75% said they would switch doctors to receive virtual sexual health consultations; 66% said the same about mental health services; 56% said they would switch for prescription refills.

    Improving Support for HPV Vaccination Through Persuasive Messaging
    In April 2019, Civis Analytics surveyed 2,491 U.S. parents of children under 18 (weighted to be representative of the American public), and found that while 83% of all respondents have heard of HPV, few are well-informed about the virus. After asking a series of true/false questions to parents, only 6% correctly answered all statements, while 20% did not answer any of the questions correctly.

    The survey respondents were then divided into four groups, three that saw a message related to HPV vaccination, and one control group that did not see a message. Civis asked respondents how important they believe it is for children to receive the HPV vaccination before the age of 14 both before and after seeing one of these messages (or the control). After data collection, Civis built and ran a statistical model that calculated the impact of each message on support for HPV vaccination, controlling for respondent characteristics.

  • The "HPV Causes Cancer" message emphasized HPV health risks (including various cancers) as well as success of the HPV vaccination in reducing the incidence of these outcomes.
  • The "HPV Is Common" message emphasized that HPV is the most common sexually transmitted infection, and nearly half of all new infections occur in and are transmitted by teens and young adults of both sexes.
  • The "HPV Vaccine Is Safe" message highlighted that the HPV vaccination has a reassuring safety record backed by years of monitoring and research, and has only minor side effects, with no evidence that the vaccine causes cancer or infertility.
  • This test found that informing parents about the negative health outcomes associated with HPV (the "HPV Causes Cancer" message) is the message most likely to increase support for vaccinations. Although concern about side effects was the most common reason given for not vaccinating, the "HPV Vaccine is Safe" message was not effective at increasing support for vaccination, and in fact could cause backlash (a net decrease in support).

    "More than ever, healthcare services and technologies are considerate of patient attitudes and desires as they innovate and evolve," said Crystal Son, who leads Civis Analytics's healthcare practice. "The concept of 'consumerization of healthcare' depends on a full understanding of the patient outside of the clinical setting, though. We're hoping this new series sheds some light on how consumers feel, think, and act when it comes to healthcare."

    The full studies are available here.

    About Civis Analytics
    Civis Analytics helps leading public and private sector organizations use data to gain a competitive advantage in how they identify, attract, and engage people. With a blend of proprietary data, technology and advisory services, and an interdisciplinary team of data scientists, developers, and survey science experts, Civis helps organizations stop guessing and start using statistical proof to guide decisions. Learn more about Civis at www.civisanalytics.com.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/civis-analytics-kicks-off-voice-of-the-patient-research-series-with-new-studies-on-telehealth-and-hpv-vaccination-300954217.html

    SOURCE Civis Analytics

    Eintrag hinzufügen
    Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
    Es ist ein Fehler aufgetreten!